PMID- 15447754
OWN - NLM
STAT- MEDLINE
DCOM- 20041202
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 99
IP  - 10
DP  - 2004 Oct
TI  - Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on 
      clinical, biochemical, and metabolic parameters of patients with nonalcoholic 
      steatohepatitis.
PG  - 1946-52
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) has been incriminated to play 
      an important role in the pathogenesis of nonalcoholic steatohepatitis (NASH). 
      Pentoxifylline, a TNF-alpha inhibitor could prove useful in treating patients 
      with NASH. METHODS: Eighteen patients (mean age, 34 +/- 7.8 yr) with 
      histologically proven NASH and with persistently elevated ALT (>1.5 times) were 
      given pentoxifylline at a dosage of 400 mg t.i.d. for 6 months. No lipid-lowering 
      agent or antioxidants were concurrently advised. RESULTS: Impaired fasting 
      glycemia, impaired glucose tolerance, diabetes mellitus, and hypertriglyceridemia 
      were noted in 6, 35, 17, and 53% of the patients, respectively. After 6 months of 
      therapy, fatigue improved (55.6 vs 20%, p= 0.016), but serum triglyceride (182 
      +/- 66 vs 160 +/- 55 mg/dl, p= 0.397), cholesterol (173 +/- 46 vs 162 +/- 40 
      mg/dl, p= 0.440), and body mass index (BMI) (27.3 +/- 3.1 vs 26 +/- 3.1 kg/m(2), 
      p= 0.087) remained unchanged. Mean AST (66 +/- 29 vs 33 +/- 11 IU/l, p < 0.0001) 
      and ALT (109 +/- 44 vs 47 +/- 20 IU/l, p < 0.0001) reduced significantly. ALT 
      normalized in 23% at month 1 (p= 0.125), 35% at month 2 (p= 0.125), and 60% at 
      month 6 (p= 0.008) of treatment. The insulin resistance index assessed by 
      homeostatic metabolic assessment (HOMA(IR)) improved (5.1 +/- 3.4 vs 2.6 +/- 2, p 
      = 0.046) and the serum TNF-alpha reduced significantly after therapy (22.15 +/- 
      2.49 vs 17 +/- 2.58 pg/ml, p = 0.011). The drug was well tolerated. CONCLUSIONS: 
      In patients with NASH, pentoxifylline therapy effectively achieved significant 
      clinical and biochemical improvement with reduction in HOMA(IR). These benefits 
      are possibly mediated through suppression of TNF-alpha.
FAU - Satapathy, Sanjay K
AU  - Satapathy SK
AD  - Departments of Gastroenterology and Pathology, GB Pant Hospital, New Delhi 
      110-002, India.
FAU - Garg, Sanjay
AU  - Garg S
FAU - Chauhan, Ranjeet
AU  - Chauhan R
FAU - Sakhuja, Puja
AU  - Sakhuja P
FAU - Malhotra, Veena
AU  - Malhotra V
FAU - Sharma, Barjesh C
AU  - Sharma BC
FAU - Sarin, Shiv K
AU  - Sarin SK
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - SD6QCT3TSU (Pentoxifylline)
SB  - IM
MH  - Adult
MH  - Fatty Liver/complications/diagnosis/*drug therapy/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pentoxifylline/*therapeutic use
MH  - Pilot Projects
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2004/09/28 05:00
MHDA- 2004/12/16 09:00
CRDT- 2004/09/28 05:00
PHST- 2004/09/28 05:00 [pubmed]
PHST- 2004/12/16 09:00 [medline]
PHST- 2004/09/28 05:00 [entrez]
AID - AJG40220 [pii]
AID - 10.1111/j.1572-0241.2004.40220.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2004 Oct;99(10):1946-52. doi: 
      10.1111/j.1572-0241.2004.40220.x.